Latest Articles

Publication Date
Dissecting endometrial cancer complexity in response to standard and targeted therapies - Nature

Dissecting endometrial cancer complexity in response to standard and targeted therapies Nature

Published: Nov. 28, 2025, 5:08 p.m.
Exploring the combined antiproliferative effects of artesunate and resveratrol in Ishikawa endometrial cancer cells - News-Medical

Exploring the combined antiproliferative effects of artesunate and resveratrol in Ishikawa endometrial cancer cells News-Medical

Published: Nov. 27, 2025, 10:29 a.m.
DESTINY-Endometrial01 Will Examine T-DXd Plus Rilvegostomig or Pembrolizumab in HER2+ pMMR Endometrial Cancer - OncLive

DESTINY-Endometrial01 Will Examine T-DXd Plus Rilvegostomig or Pembrolizumab in HER2+ pMMR Endometrial Cancer OncLive

Published: Nov. 26, 2025, 7:03 p.m.
NICE recommends treatment for primary advanced or recurrent endometrial cancer - Pf Media

NICE recommends treatment for primary advanced or recurrent endometrial cancer Pf Media

Published: Nov. 26, 2025, 4:10 p.m.
Expert explains how weight cycling raises endometrial cancer risk | Tap to know more | Inshorts - Inshorts

Expert explains how weight cycling raises endometrial cancer risk | Tap to know more | Inshorts Inshorts

Published: Nov. 26, 2025, 11:03 a.m.
Network pharmacology prediction of UA in targeting endometriosis progression to endometrial cancer.

Endometriosis is a gynecological disorder predominantly affecting women of reproductive age and is considered a potential risk factor for the development of endometrial cancer. However, the molecular mechanisms underlying the …

Published: Nov. 26, 2025, midnight
A STEM educator battles rare endometrial cancer - UT Physicians

A STEM educator battles rare endometrial cancer UT Physicians

Published: Nov. 25, 2025, 9:25 p.m.
NICE Recommends Jemperli With Chemotherapy for Advanced Endometrial Cancer - NAVLIN DAILY

NICE Recommends Jemperli With Chemotherapy for Advanced Endometrial Cancer NAVLIN DAILY

Published: Nov. 25, 2025, 2:06 p.m.
HAS Renews Early Access for Jemperli in Advanced Endometrial Cancer - NAVLIN DAILY

HAS Renews Early Access for Jemperli in Advanced Endometrial Cancer NAVLIN DAILY

Published: Nov. 24, 2025, 12:18 p.m.
Mesonephric-like Adenocarcinoma (MLA) Diagnostic Criteria and Controversies: Perspectives and Guidance From Pathologists in the MLA Consortium.

Mesonephric-like adenocarcinoma (MLA) is a rare and aggressive gynecologic malignancy that has only been recognized in the last decade. It arises in the endometrium, ovaries, and other extrauterine sites (often …

Published: Nov. 24, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!